These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24345487)

  • 1. [Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor].
    Zheng L; Lin B; Song Z; Xie F; Hong W; Feng J; Shao L; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):632-8. PubMed ID: 24345487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.
    Huang WF; Liu AH; Zhao HJ; Dong HM; Liu LY; Cai SX
    Medicine (Baltimore); 2015 Aug; 94(33):e1263. PubMed ID: 26287412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.
    Nie W; Tao X; Wei H; Chen WS; Li B
    Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
    Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
    Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
    Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
    J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.
    Isobe K; Hata Y; Tochigi N; Kaburaki K; Kobayashi H; Makino T; Otsuka H; Sato F; Ishida F; Kikuchi N; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Iyoda A; Homma S
    J Thorac Oncol; 2014 Apr; 9(4):483-7. PubMed ID: 24736070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma].
    Qian K; Zhang Y; Zhi X
    Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):543-548. PubMed ID: 28855035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Viteri S; González-Cao M; Morales-Espinosa D; Verlicchi A; Crisetti E; Chaib I; Santarpia M; Luis Ramírez J; Bosch-Barrera J; Felipe Cardona A; de Marinis F; López-Vivanco G; Miguel Sánchez J; Vergnenegre A; Sánchez Hernández JJ; Sperduti I; Bria E; Rosell R
    Sci Rep; 2015 Dec; 5():17499. PubMed ID: 26639561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
    Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
    Hong W; Lin B; Zhang B; Mao W; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):321-6. PubMed ID: 24758907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
    Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
    Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
    Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
    Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
    Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
    Cardona AF; Ordóñez-Reyes C; Ruiz-Patiño A; Garcia-Robledo JE; Barron LZ; Recondo G; Rojas L; Corrales L; Martín C; Barrón F; Sotelo C; Rodríguez J; Ricaurte L; Rolfo C; Ávila J; Mayorga D; Archila P; Otero J; Mas L; Bermudez M; Gamez T; Carranza H; Vargas C; Rosell R; Arrieta O
    JCO Precis Oncol; 2021 Nov; 5():839-848. PubMed ID: 34994616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.